Skip to main content

Boston Scientific statistics

  • BSX · NYSE
  • Medical devices
  • Health Care Equipment
  • S&P 500
$44.34+0.32%Close 13 Nov 2026 · Market value $63.86B

Valuation and share-price figures are struck on the latest close (13 Nov 2026); the others are read from the company's reports. A figure that cannot be worked out, such as a P/E after a loss, is left out.

Valuation

Boston Scientific is valued at $63.86B on its latest close. Its price is 18.2 times its earnings.

Market value$63.86B
Enterprise value$75.86B
Price / earnings18.23
Price / sales3.03
Price / book2.49
EV / EBITDA14.14
EV / sales3.60
Price / free cash flow19.17
Price / free cash flow, own 5-year average55.45
EV / EBIT19.13
EV / free cash flow22.58
Free cash flow yield5.2%

Share price

Latest close$44.34
Day's change+0.3%
52-week high$105.65
52-week low$39.57
From 52-week high−58.0%
Return · 1 month−0.1%
Return · 3 months−10.2%
Return · year to date−53.5%
Return · 1 year−57.4%
Beta · 1 year against the S&P 5000.25
50-day average$44.01
200-day average$54.14
RSI 1450.4
Average volume · 20 sessions20.1M

Margins and returns

For fiscal 2025, as filed.

Gross margin69.0%
Operating margin18.0%
Net margin14.4%
Free cash flow margin18.2%
Return on equity12.6%
Return on assets7.4%
Return on invested capital8.6%
Return on invested capital, 5-year average5.9%
Return on capital employed10.1%
Stock-based compensation / revenue1.5%

Financial position

At the end of fiscal 2025.

Cash and equivalents$1.97B
Total debt$11.97B
Net debt$10.01B
Current ratio1.62
Quick ratio0.10
Debt / equity0.49
Net debt / EBITDA2.01
Interest coverage10.35

Growth

Revenue, latest quarter on a year+1.4%
Revenue, twelve months on a year+8.9%
EPS, latest quarter on a year−21.6%
EPS, twelve months on a year+26.6%
Revenue, 5-year compound+15.2%
Revenue, 10-year compound+9.5%
Free cash flow, 5-year compound+26.4%

Shares and dividends

For fiscal 2025, as filed.

Diluted shares1.5B
Shares outstanding, 5-year compound+1.1%

Taxes

For fiscal 2025, as filed.

Income tax expense$493.0M
Effective tax rate14.6%

BSX in the terminal

Valuation against the company's own history, a cash-flow valuation, peers, charts and alerts.